Papulopustular eruptions associated with EGFR-pathway-related targeted therapies: clinical spectrum, evidence boundaries, folliculocentric inflammation, and management considerations.
Аннотация
Papulopustular eruption is a characteristic dermatologic toxicity of classical epidermal growth factor receptor (EGFR) inhibitors and may impair quality of life, supportive-care needs, and treatment continuity. Although frequently termed acneiform, it is distinct from acne vulgaris and is better understood as a therapy-associated folliculocentric inflammatory eruption. Related papulopustular phenotypes have been reported with MEK inhibitors and newer EGFR-targeting regimens such as amivantamab, but these settings differ in pharmacology, evidence base, and clinical behavior. This Mini Review summarizes these eruptions across three evidence contexts: classical EGFR inhibitor-associated eruption, MEK inhibitor-associated overlapping eruption, and amivantamab-associated scalp-predominant disease in an EGFR/MET bispecific-antibody setting. We discuss mechanisms using an evidence-tiered approach, distinguishing relatively direct evidence for KLF4/IL-36γ signaling and Cutibacterium acnes-amplified neutrophilic inflammation from emerging or hypothesis-generating links involving hair-follicle immune dysregulation, JAK-associated signaling, and destructive scalp phenotypes. Finally, we outline evidence-aware management considerations, separating guideline-supported conventional care from lower-level evidence for refractory, superinfected, or scalp-destructive presentations.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.